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SUMMARY
Understanding the root causes of autoimmune diseases is hampered by the inability to access relevant hu-
man tissues and identify the time of disease onset. To examine the interaction of immune cells and their
cellular targets in type 1 diabetes, we differentiated human induced pluripotent stem cells into pancreatic
endocrine cells, including b cells. Here, we describe an in vitro platform that models features of human
type 1 diabetes using stress-induced patient-derived endocrine cells and autologous immune cells. We
demonstrate a cell-type-specific response by autologous immune cells against induced pluripotent stem
cell-derived b cells, along with a reduced effect on a cells. This approach represents a path to developing
disease models that use patient-derived cells to predict the outcome of an autoimmune response.
INTRODUCTION
Type 1 diabetes (T1D) results from an autoimmune destruction of
insulin-secreting pancreatic b cells (World Health Organization,
2016). Genetic and environmental factorsmay render b cells sus-
ceptible to attack by the immune system and contribute to b cell
dysfunction (van Belle et al., 2011; Pugliese, 2013); however, the
exact triggers and progression to clinical onset are not fully
understood.
Insulin accounts for up to 50% of protein production in b cells,
and this increases in response to metabolic demand (Scheuner
and Kaufman, 2008; Schuit et al., 1988). Consequently, b cells
are prone to endoplasmic reticulum (ER) stress and protein mis-
folding that can lead to b cell failure (Engin, 2016). It has also
been suggested that the onset of T1D is associated with viral
infection (Hober and Sauter, 2010), b cell exposure to chemicals
(Like and Rossini, 1976), reactive oxygen species (Delmastro
and Piganelli, 2011), and inflammation (Eizirik et al., 2013). All
of these environmental triggers can cause b cell ER stress, sug-
gesting that ER stressmay be a common factor in disease onset.
T1D was a lethal disease until the discovery of insulin in the
1920s, and since then, insulin injection remains the primary treat-
ment for T1D patients (Banting et al., 1922). The transplantation
of cadaveric islets along with immunosuppression has been suc-
cessfully performed to treat T1D (Shapiro et al., 2000). The chal-
lenges associated with transplantation, including the paucity of
available human islets and allogeneic immune responses, may
be overcome through the use of patient induced pluripotent
stem cell-derived b cells (iPSC-b). Human iPSC-b cells could
have the potential to replace the function of the b cells lost in
T1D (Pagliuca et al., 2014; Veres et al., 2019; Nair et al., 2019;
Russ et al., 2015; Rezania et al., 2014), thereby reducing or elim-
inating the need for exogenous insulin. However, it is expected
that autologous iPSC-b cells will still be vulnerable to recurrent
autoimmunity following transplantation (Sutherland et al., 1984;
Sibley et al., 1985). Immune evasion strategies, including encap-
sulation with biomaterials or genetic manipulation, represent
ways forward in advancing iPSC-b cell transplant therapies.
Developing such strategies would benefit from a model that
can predict tissue rejection in T1D patients. Here, we describe
an in vitro platform using iPSC-b and iPSC-a cells that recapitu-
lates some aspects of the autologous immune interaction in hu-
man T1D. This platform makes it possible to more intently study
human autoimmune interactions and may be used for immuno-
genic evaluation before cell replacement therapy.
RESULTS
Immune Profiling of In Vitro-Generated Patient-Derived
b and a Cells
iPSCs were derived from three T1D donor (T1D1–3) and one non-
T1D (ND) donor (Figure 1A; Table S1). After iPSC characteriza-
tion (Figures S1A and 1B), cells were differentiated in vitro using
two different protocols to produce islet-like clusters that are
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Figure 1. Immune Profiling of In Vitro-Generated Patient-Derived b and a Cells
(A) Schematic of the differentiation workflow.
(B) Immunostaining of an iPSC-b cluster.
(C andD) Flow cytometry quantification of C-peptide- and glucagon-positive cells in the b-cell differentiation protocol (C) and a-cell differentiation protocol (C). n =
3 T1D and n = 1 ND donor, n = 3–7 differentiation batches per donor line.
(E and F) Flow cytometry quantification of HLA-A, -B, and -C iPSC-b clusters treated with thap (5 mM for 5 h) or IFNg (100 U/mL, 48 h), gated on C-peptide-positive
cells (E) and glucagon-positive cells (F). The values are represented as adjusted mean fluorescence intensity (MFI). n = 3 T1D and n = 1 ND donor, n = 3 dif-
ferentiation batches per donor line. T1D1, T1D2, and T1D3 were pooled together.
(G) Relative mRNA expression of T1D-associated autoantigens in clusters untreated or treated with thap (5 mM for 5 h). Each column represents a donor and each
row represents a gene. n = 3 T1D, n = 1 ND donor, n = 4 control human islets.
**p < 0.01 and ***p < 0.0005. Ordinary 1-way ANOVA. ns, non-significant. See also Figure S1.
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enriched in either insulin-producing iPSC-b cells (Veres et al.,
2019) or glucagon-producing iPSC-a cells (Peterson et al.,
2020) (b cell and a differentiation protocol, respectively) (Fig-
ure 1A). The efficiency of b or a cell generation varies between
PSC lines, yet both the T1D and ND iPSC lines were able to
differentiate into iPSC-b or iPSC-a clusters. The differentiation
protocols produced 20% of the desired cell type (Figures
1B–1D), similar to previous reports using iPSC lines (Millman
et al., 2016). While these designations indicate the predominant
endocrine cell type in each protocol, iPSC-b clusters also have
glucagon-producing a cells (10%) and vice versa (5%) (Figures
1B–1D, S1C, and S1D). These iPSC-b and -a cell-enriched prep-
arations were used as autologous targets for immune studies,
with peripheral blood mononuclear cells (PBMCs) isolated from
the corresponding donors.
Little is known about the immunogenicity of iPSC-b or iPSC-a
cells (van der Torren et al., 2017). The human leukocyte antigen
complex (HLA) gene locus is the top risk allele in T1D (Pociot,
2017), and HLA expression is required for a robust adaptive im-
mune response (Clark et al., 2017). Since our goal was to recapit-
ulate immune interactions thatmayoccur inT1Dpathogenesis,we
investigated the expression of molecules relevant to T cell recog-
nition in iPSC-band iPSC-a fromT1DandNDdonors instresscon-
ditions. The iPSC-a and -b cell preparationswere treated with sol-
uble interferon gamma (IFNg) to mimic inflammatory stress and
thapsigargin (thap) to induce ER stress (Kracht et al., 2017; Marre
et al., 2018). Following IFNg (Richardson et al., 2016) but not by
thap treatment alone, iPSC-b and iPSC-a cells upregulated HLA
class I (HLA-ABC) and other immunoregulatory molecules,
includingprogrammeddeath-ligand1 (PD-L1) andFascell surface
death receptor (FasR) (see Figures S1G–S1P, 1E, and 1F). The
expression of molecules relevant to immune recognition was
similar in bothND and T1D iPSC-a and -b cells. The IFNg-induced
upregulated HLA-ABC protein expression was the same between
iPSC-b cells and human islets following cytokine treatment. The
HLA-ABC expression was lower in resting iPSC-a and -b cells
compared to control islets (Figure S1Q).
Several islet proteins have been identified as targets of
autoimmunity in T1D, including proinsulin (INS), glutamic acid
decarboxylase (GAD), tyrosine phosphatase-like insulinoma-
associated antigen 2 (IA-2, PTPRN), islet-specific glucose-6-
phosphatase catalytic subunit–related protein (G6PC2), the
cation efflux transporter ZNT8 (SLC30A8), islet-amyloid poly-
peptide (IAPP), and others (Pugliese, 2017). CD8 T cell epitopes
from these proteins have been identified in the PBMCs of recent-
onset T1D patients, suggesting a role in b cell destruction (Velth-
uis et al., 2010). We determined the relative transcript expression
encoding these protein targets in derived iPSC-b or -a cells. We
found similar levels of mRNA in iPSC-b cells, albeit low in some
cases, for G6PC2, SLC30A8, IAPP, INS, GAD, and IA-2 in both
T1D and ND iPSC-b cells and in islets isolated from a control
donor (Figure 1G).
TCells AreActivatedWhenCo-culturedwith Autologous
ER-Stressed iPSC-b Cells
To examine the interaction between iPSC-b and immune cells,
we co-cultured autologous PBMCs with their corresponding
iPSC-b cell clusters. Immune activation was evaluated by sur-
face staining of T cell activation markers and by cytokine secre-
tion after a 48-h co-culture.
We assessed the immune response of autologous PBMCs
when co-cultured with iPSC-b clusters from ND and T1D donors
(Figure 2A). As a positive control, PBMCs were stimulated with
anti-CD3/CD28 beads (Figures S2A–S2C). T cell activation was
not observed when autologous PBMCs were co-cultured with
the corresponding untreated iPSC-endocrine cells (Figure 2).
Similarly, iPSC-b pre-stimulated with IFNg to enhance antigen
presentation did not elicit an immune response (Figures S2E
and S2F). Previous studies have reported that b cell ER stress
has implications for immunogenicity in T1D. ER stress has
been shown to increase b cell immunogenicity and can lead to
T1D (Eizirik et al., 2008). To mimic ER stress, iPSC-b cells were
pre-treated with thapsigagin (thap) for 5 h before co-culturing
with PBMCs for 48 h. Thap treatment of PBMCs alone did not
induce T cell activation (Figure S2D).
Co-culturing PBMCs with autologous T1D and ND iPSC-b,
pre-treated with thap, resulted in upregulated immune cell acti-
vation markers CD25 and CD69 on T cell populations (Figures
2B, 2C, and S2G) and in increased levels of IFNg, interleukin-2
(IL-2), IL-17, and C-X-C motif ligand 10 (CXCL10) (Figure 2D).
Both CD69, a type II C-lectin receptor, and CD25, the high-affin-
ity IL-2 receptor-a chain, are early activation markers expressed
rapidly by human conventional CD8 and CD4 T cells following
T cell receptor (TCR) engagement (Cibrián and Sánchez-Madrid,
2017; Caruso et al., 1997).We also observed a decrease in viable
iPSC-b in the thap-treated co-culture experiments (Figures 2E
and S4G). These results support a causal role of ER stress in elic-
iting an immune response, as previously reported by others.
Autologous co-culture with iPSC-b with PBMCs induced an im-
mune response in both T1D donors and ND donors. These ob-
servations are in line with reports describing that islet-reactive
T cell frequencies in the blood do not distinguish T1D from ND
individuals (Culina et al., 2018).
Next, we performed experiments to determine whether the
observed T cell activation within the PBMCs is mediated by
direct TCR engagement with the HLA complex on iPSC-b cells,
rather than a T cell bystander activation caused by the inflamma-
tory cytokine milieu or engagement of co-stimulatory molecules
by other cells present in the PBMCs. First, the iPSC-b target cells
were pre-treated with an HLA class I blocking antibody to pre-
vent TCR binding to the peptide-HLA complex (Figures 3A, 3B,
S3A, and S3D). Second, we used a transwell co-culture system
that precludes contact between the immune cells and iPSC-b
(Figure 3C). Third, iPSCs were transduced with a B2M guide
RNA and Cas9, leading to the decreased expression of HLA
class I on differentiated iPSC-b cells (Figures 3D, S3B, and
S3C). In all three experiments, reduced T cell activation was as-
sessed by cytokine secretion and evaluation of the T cell activa-
tion markers CD25 and CD69 in CD8+ T cells present in the
PBMCs. These results support the conclusion that T cell activa-
tion is mediated by direct TCR engagement of peptide-HLA
complexes on iPSC-b.
Activation and Killing by T Cells Is Selective for iPSC-b
The main feature of T1D is selective destruction of pancreatic b,
but not a, cells. To test whether the in vitro platform recapitulates
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that specificity, we generated additional iPSC-derived cell
types—autologous iPSC-a cells and iPSC-cardiomyocytes—
and performed co-culture experiments, as described above (Fig-
ure 4A). All of the cell preparations (iPSC-b, iPSC-a, and cardio-
myocytes) were pre-treated with thap before co-culturing with
PBMCs.
T cell activation was restricted to co-culture with autolo-
gous iPSC-b cells and not to other iPSC-derived cells (Figures
4B, 4C, 4F, S2G, and S4A–S4C). Since b cells are highly
secretory cells and more likely to undergo ER stress, we set
out to evaluate whether the T cell response induced by
iPSC-b was due to the resistance of iPSC-a to ER stress.
Both iPSC-b and -a cells showed an increase in ER stress-
related proteins, PRKR-like ER kinase (PERK), protein disul-
fide isomerase (PDI), and binding immunoglobulin protein
(BiP) after thap treatment, demonstrating that both cell types
A
D E
B
C
Figure 2. T Cells Are Activated When Co-cultured with Autologous ER-Stressed iPSC-b
(A) Experimental design: PBMCs co-cultured with autologous iPSC-b.
(B–D) Flow cytometry data of T cells after a 4-8h co-culture with iPSC-b cells (n = 3 T1D and n = 1 ND donor, n = 3 differentiation batches per donor line). T1D1,
T1D2, and T1D3 were pooled together.
(B) CD25+ and (C) CD69+ co-positive for CD3+, CD4+, or CD8+ cells, as indicated. The values are represented as adjusted MFI.
(D) Pro-inflammatory cytokine detection in supernatants collected after 48 h co-culture of PBMC with iPSC-b (n = 3 T1D and n = 1 ND donor, n = 3 differentiation
batches per donor line). T1D1, T1D2, and T1D3 were pooled together.
(E) Percentage of live iPSC-b after co-culture, gated for C-peptide+/glucagon (n = 3 T1D and n = 1 ND donor, n = 3 differentiation batches per donor line). T1D1,
T1D2, and T1D3 were pooled together.
*p < 0.05, **p < 0.01, ***p < 0.0005, and ****p < 0.0001. Ordinary 1-way ANOVA. ns, non-significant. See also Figure S2.
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Figure 3. iPSC-b-Induced T Cell Activation and Killing Is Mediated by Direct T Cell-HLA Interaction
(A and B) PBMCs co-cultured for 48 h with autologous iPSC-b (n = 3 T1D donors, 3 differentiation batches per donor). iPSC-bwere pre-treated with thap (5 mM for
5 h) and/or anti-HLA antibody for 30 min before co-culture.
(A) Flow cytometry after 48 h co-culture of T cell activation markers, CD25+ and CD69+, gated on CD8+ cells.
(B) Pro-inflammatory cytokine detection in supernatants collected after 48 h co-culture of PBMCs with autologous iPSC-b ± thap.
(C) Expression of CD25+ and CD69+, gated on CD8+ cells in a transwell system.
(legend continued on next page)
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are sensitive to ER stress induction in vitro (Figures S1E and
S1F).
To further explore iPSC-b cell specificity, we investigated
whether iPSC-a cells are protected from T cell-mediated
destruction compared to iPSC-b cells after autologous co-cul-
ture with PBMCs. We compared b and a cell numbers from their
respective differentiation protocols (a versus b differentiation
protocol) using two assays for survival after autologous co-cul-
ture with PBMCs: the percentage of live a and b cells by live
cell count (Figures 4D, S4E, and S4F) and assessing apoptosis
using the apopxin dye (Figures 4E and S4G).We found that fewer
iPSC-b cells survive co-culture with autologous PBMCs
compared to iPSC-a cells, and more iPSC-b cells are apoptotic
compared to iPSC-a cells.
Since we observed a low activation of autologous immune
cells in the presence of iPSC-a cells, we performed a co-culture
experiment using unmatched PBMCs to test whether iPSC-a
can induce an allogeneic T cell response. Allogeneic T cells up-
regulated the activation markers after co-culture with iPSC-a
cells (Figure 4G). These results show that iPSC-a cells can be
immunogenic and induce T cell reactivity in an allogeneic setting.
Our in vitro differentiation system generates a mixed popula-
tion of endocrine cells. It is thus difficult to demonstrate whether
the effects are cell specific or dependent on other cell types in
the preparation. To address the question of b cell specificity,
we used anti-CD49a staining to sort out iPSC-b cells. The nega-
tive fraction of the CD49a sorted cells was stained with CD26 to
sort iPSC-a cells (Veres et al., 2019). This two-step method
yields clusters of up to 80% b cells by CD49a sorting and up
to 50% a cells by CD26 sorting (Figure S4D). After enriching
both b and a cell populations, we performed co-culture experi-
ments comparing both enriched populations and the original
mixed population derived from the standard iPSC-b protocol.
Co-culture with both enriched and standard iPSC-b cell clusters
has similar levels of T cell activation while the a cell population
induced minimal activation (Figure 4H). In summary, we show
that an autoreactive, b cell-specific response can be achieved
in vitro using iPSC-b cells and autologous immune cells, recapit-
ulating key features of T1D.
DISCUSSION
A deeper understanding of the immunopathogenesis of T1D,
including how it differs among T1D individuals, is needed to
develop rational strategies to find a cure or to prevent the disease.
Recent advances in stem cell technologies and access to patient
samples provide themeans to explore T1D pathogenesis. We es-
tablishedan in vitroplatformusing iPSC-derivedpancreatic endo-
crine cells and autologous immune cells that recapitulates key as-
pectsofT1D.Wedemonstrate that the immune response tobcells
requires ER stress, that a direct, physical interaction between the
T cells and b cells is necessary, and the T cell-mediated activation
and killing is preferential to b cells, but not a cells.
The findings of this research should be interpreted in light of
two major limitations. First, these experiments required the use
of blood provided from the same patient who supplied the iPSCs
used to generate iPSC-derived cells. We had to synchronize the
time of cell generation with donor availability to obtain blood to
perform the experiments. Second, cell numbers are a limitation
for the co-culture experiments, since wewere only able to isolate
on average 50 million PBMCs from each blood draw. The
approach would be strengthened by improving techniques to
select and culture circulating pancreatic b cell-reactive immune
cells. A better source of pancreatic b cell-reactive immune cells
may be the draining pancreatic lymph nodes in T1D patients, but
these are not readily accessible.
We observed unexpected results, including the activation of
T cells by ND iPSC-b cells, the inability of IFNg to induce an im-
mune response, apart from HLA class I upregulation, and the
requirement of ER stress to induce autologous T cell activation.
We believe that iPSC-b cells mimic healthy b cells after reprog-
ramming from somatic cells, regardless of whether they were
derived from a T1D or a ND donor, thus putting both T1D and
ND iPSC-b cells on the same starting line. To mimic a b cell dis-
ease state, we had to induce ER stress in the iPSC-b cells. This
supports the idea that the trigger of b cell destruction in T1D is
enhanced b cell vulnerability caused by islet inflammation due
to ER stress. We did not observe any difference in the ability of
iPSC-b cells from T1D donors to stimulate an immune response
relative to iPSC-b cells from ND donors, and in either case, the
cells had to be subjected to ER stress to promote an immune
response. It is perhaps relevant that the pancreata of individuals
with T1D are significantly smaller than those studied from ND in-
dividuals (Regnell et al., 2016; Virostko et al., 2019), and even
that first-degree relatives of an index case with T1D have smaller
pancreata (Campbell-Thompson et al., 2019). While conjectural,
it stands to reason that a metabolic load imposed on pancreatic
b cells will be greater per b cell when there are fewer such cells to
carry the load.
We observed that T cell activation was restricted to co-culture
with the autologous iPSC-b cell preparation and not to the iPSC-
a or cardiomyocyte preparation. iPSC-b cells expressed genes
encoding peptides associated with T1D. Although we did not
assess natural processing and presentation or verify peptide
modification in the iPSC-derived cells, CD8+ T cells within
PBMCs responded to stressed iPSC-b, suggesting that b cell-
specific epitopes were generated. The importance of ER stress
and the unfolded protein response in b cell pathophysiology
and the autoimmune responses in T1D are not well understood
(Marre et al., 2018; Eizirik et al., 2008). Our results add to this
narrative by showing that ER stress in b cells is an important
trigger for an immune response in vitro. Experiments using
(D) Expression of the activation marker CD25+ and CD69+ on CD8+ cells after 48-h co-culture with autologous iPSC-b transduced with a lentivirus vector ex-
pressing a non-targeting (NT) or B2M guide RNA (gRNA) and Cas9 (n = 3 T1D donors, n = 3 differentiation batches per donor line). *p < 0.05 and **p < 0.01,
Student’s t test. T1D1, T1D2, and T1D3 were pooled together. ns, non-significant.
(A–C) n = 3 T1D donors, n = 3 differentiation batches per donor line. T1D1, T1D2, and T1D3 were pooled together. *p < 0.05, **p < 0.005, and ***p < 0.0005; 2-way
ANOVA.
See also Figure S3.
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islet-specific T cell lines would take advantage of the systempre-
sented here and potentially strengthen the analysis and conclu-
sions. It is unfortunate that the coronavirus disease 2019
(COVID-19) pandemic lockdown eliminated the possibility of ob-
taining the necessary patient blood samples for months, and we
therefore could not perform these experiments. Our protocol for
assessing antigen-specific T cell activation was the expression
of both CD25 and CD69 on T cells (Caruso et al., 1997). A signif-
icant proportion of both CD8 and CD4 T cells are positive for
CD69 expression, which may reflect the increased levels of in-
flammatory cytokines detected within the cultures. In contrast,
expression of CD25 by human conventional CD8 and CD4
T cells is a better measure of antigen-specific stimulation of
T cells and less likely to be significantly upregulated by cytokines
alone (Shatrova et al., 2016). We postulate that the PBMC-iPSC-
b cell co-cultures created an environment in which ER-stressed
iPSC-b cells are presenting/releasing autoantigens and creating
an inflammatory milieu that strongly stimulates autoreactive
T cells to express CD25 and CD69 and that causes bystander
T cells to upregulate CD69.
CD8+ T cells play a fundamental role in T1D pathogenesis, as
they take center stage in the destruction of pancreatic b cells and
contribute to sustained islet inflammation (Coppieters et al.,
2012). Although we also observed CD4+ activation after co-
culturing PBMCs and iPSC-b cells, we speculate that this activa-
tion is due to antigen presentation by professional antigen-pre-
senting cells present in the PBMC preparation. However, we
observed low levels of HLA-DR on iPSC-b that could be involved
in HLA class II peptide presentation by b cells leading to CD4+
T cell activation. Further investigation is necessary to elucidate
the mechanism by which CD4+s are activated in this system.
In summary, the in vitro platform described here can be used
to better understand the cellular and molecular components
relevant to immune cell interaction in human T1D. In addition, it
opens the possibility of testing for the immune protection of tol-
erogenic engineered iPSC-b cells before cell replacement
therapy. Genetically engineered iPSCs that evade immune
destruction may ultimately reduce the need for harmful immuno-
suppression (Han et al., 2019; Deuse et al., 2019). Finally, our
model can pave the way to the development of other disease
models that take advantage of patient-derived cells to predict
the outcome of an autoimmune response.
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Figure 4. Activation and Killing by T Cells Is Selective for iPSC-b
(A) Experimental design: PBMCs co-cultured with autologous iPSC-derived cells.
(B, C, and F) CD25 or CD69 expression shown as MFI.
(B) PBMCs (gated on CD3+, CD4+, and CD8+ populations) co-cultured for 48 h with autologous iPSC-b (purple) or iPSC-a (red). (n = 3 T1D and n = 1 ND donor,
n = 3 differentiation batches per donor line). T1D1, T1D2, and T1D3 were pooled together.
(C) Donor-matched PBMCs (CD3+ gated) (n = 1 T1D, n = 3 differentiation batches per donor line) co-cultured for 48 h with autologous iPSC-b (purple) or iPSC-
cardiomyocytes (orange).
(D) Percentage of live iPSC-b (C-peptide+/glucagon) or iPSC-a (C-peptide/glucagon+) from iPSC-b or iPSC-a differentiations, respectively (n = 3 T1D donors,
n = 3 differentiation batches per donor line). T1D1, T1D2, and T1D3 were pooled together.
(F) Representative flow cytometry histograms after 48 h of co-culture. Dashed histogram represents the control (untreated target cells).
(E) Percentage of apoptotic (apopxin+) iPSC-b (CD49a+/CD26) or iPSC-a (CD49a/CD26+) from iPSC-b or iPSC-a differentiations (n = 1 T1D iPSC donor, n = 3
differentiation batches per donor line).
(G) Unmatched PBMCs (CD3+ gated cells) co-cultured for 48 h with iPSC-a (n = 3 T1D donors, n = 3 differentiation batches per donor line). T1D1, T1D2, and T1D3
were pooled together.
(H) Donor-matched PBMCs (gated on CD3+, CD4+, and CD8+ populations) co-cultured for 48 h with autologous enriched iPSC-b or iPSC-a.
Data are means ± SEMs, 2-way ANOVA. *p < 0.05, **p < 0.005, ***p < 0.0005, and ****p < 0.0001; ns, non-significant. See also Figure S4.
8 Cell Reports 32, 107894, July 14, 2020
Report
ll
OPEN ACCESS
Helmsley Charitable Trust (2015PG-T1D044), JDRF (5-SRA-2014-284-Q-R),
National Institutes of Health (NIH): NIH UO1DK104218, NIH R24OD0426640,
and NIH UC4DK104218, and the JPB Foundation (award no. 1094).
AUTHOR CONTRIBUTIONS
N.C.L. and E.S. conceived the study. The experiments were performed by
N.C.L. and E.S. T.B.M. provided technical support and conceptual advice.
M.A.B., D.L.G., and D.M.H. were involved in the experimental design and pa-
tient recruitment and advised on the project. N.C.L., E.S., and D.A.M. wrote the
manuscript. D.A.M. designed and supervised the research.
DECLARATION OF INTERESTS
D.A.M. is a founder of Semma Therapeutics and an advisor to Vertex, who
have licensed technologies developed in the Melton lab. All of the other au-
thors declare no competing interests.
Received: January 13, 2020
Revised: May 1, 2020
Accepted: June 21, 2020
Published: July 14, 2020
REFERENCES
Banting, F.G., Best, C.H., Collip, J.B., Campbell, W.R., and Fletcher, A.A.
(1922). Pancreatic Extracts in the Treatment of Diabetes Mellitus. Can. Med.
Assoc. J. 12, 141–146.
Campbell-Thompson, M.L., Filipp, S.L., Grajo, J.R., Nambam, B., Beegle, R.,
Middlebrooks, E.H., Gurka, M.J., Atkinson,M.A., Schatz, D.A., and Haller, M.J.
(2019). Relative Pancreas Volume Is Reduced in First-Degree Relatives of Pa-
tients With Type 1 Diabetes. Diabetes Care 42, 281–287.
Caruso, A., Licenziati, S., Corulli, M., Canaris, A.D., De Francesco, M.A., Fior-
entini, S., Peroni, L., Fallacara, F., Dima, F., Balsari, A., and Turano, A. (1997).
Flow cytometric analysis of activation markers on stimulated T cells and their
correlation with cell proliferation. Cytometry 27, 71–76.
Cibrián, D., and Sánchez-Madrid, F. (2017). CD69: from activation marker to
metabolic gatekeeper. Eur. J. Immunol. 47, 946–953.
Clark, M., Kroger, C.J., and Tisch, R.M. (2017). Type 1 Diabetes: A Chronic
Anti-Self-Inflammatory Response. Front. Immunol. 8, 1898.
Coppieters, K.T., Dotta, F., Amirian, N., Campbell, P.D., Kay, T.W., Atkinson,
M.A., Roep, B.O., and von Herrath, M.G. (2012). Demonstration of islet-autor-
eactive CD8 T cells in insulitic lesions from recent onset and long-term type 1
diabetes patients. J. Exp. Med. 209, 51–60.
Culina, S., Lalanne, A.I., Afonso, G., Cerosaletti, K., Pinto, S., Sebastiani, G.,
Kuranda, K., Nigi, L., Eugster, A., Østerbye, T., et al.; ImMaDiab Study Group
(2018). Islet-reactive CD8+ T cell frequencies in the pancreas, but not in blood,
distinguish type 1 diabetic patients from healthy donors. Sci. Immunol. 3,
eaao4013.
Delmastro, M.M., and Piganelli, J.D. (2011). Oxidative stress and redox mod-
ulation potential in type 1 diabetes. Clin. Dev. Immunol. 2011, 593863.
Deuse, T., Hu, X., Gravina, A., Wang, D., Tediashvili, G., De, C., Thayer, W.O.,
Wahl, A., Garcia, J.V., Reichenspurner, H., et al. (2019). Hypoimmunogenic de-
rivatives of induced pluripotent stem cells evade immune rejection in fully
immunocompetent allogeneic recipients. Nat. Biotechnol. 37, 252–258.
Eizirik, D.L., Cardozo, A.K., and Cnop, M. (2008). The role for endoplasmic re-
ticulum stress in diabetes mellitus. Endocr. Rev. 29, 42–61.
Eizirik, D.L., Miani, M., and Cardozo, A.K. (2013). Signalling danger: endo-
plasmic reticulum stress and the unfolded protein response in pancreatic islet
inflammation. Diabetologia 56, 234–241.
Engin, F. (2016). ER stress and development of type 1 diabetes. J. Investig.
Med. 64, 2–6.
Han, X., Wang, M., Duan, S., Franco, P.J., Kenty, J.H., Hedrick, P., Xia, Y., Al-
len, A., Ferreira, L.M.R., Strominger, J.L., et al. (2019). Generation of hypoim-
munogenic human pluripotent stem cells. Proc. Natl. Acad. Sci. USA 116,
10441–10446.
Hober, D., and Sauter, P. (2010). Pathogenesis of type 1 diabetes mellitus:
interplay between enterovirus and host. Nat. Rev. Endocrinol. 6, 279–289.
Kracht, M.J., van Lummel, M., Nikolic, T., Joosten, A.M., Laban, S., van der
Slik, A.R., van Veelen, P.A., Carlotti, F., de Koning, E.J., Hoeben, R.C., et al.
(2017). Autoimmunity against a defective ribosomal insulin gene product in
type 1 diabetes. Nat. Med. 23, 501–507.
Like, A.A., and Rossini, A.A. (1976). Streptozotocin-induced pancreatic insuli-
tis: new model of diabetes mellitus. Science 193, 415–417.
Marre, M.L., McGinty, J.W., Chow, I.T., DeNicola, M.E., Beck, N.W., Kent,
S.C., Powers, A.C., Bottino, R., Harlan, D.M., Greenbaum, C.J., et al. (2018).
Modifying Enzymes Are Elicited by ER Stress, Generating Epitopes That Are
Selectively Recognized by CD4+ T Cells in Patients With Type 1 Diabetes. Dia-
betes 67, 1356–1368.
Millman, J.R., Xie, C., Van Dervort, A., G€urtler, M., Pagliuca, F.W., and Melton,
D.A. (2016). Generation of stem cell-derived b-cells from patients with type 1
diabetes. Nat. Commun. 7, 11463.
Nair, G.G., Liu, J.S., Russ, H.A., Tran, S., Saxton, M.S., Chen, R., Juang, C., Li,
M.L., Nguyen, V.Q., Giacometti, S., et al. (2019). Recapitulating endocrine cell
clustering in culture promotes maturation of human stem-cell-derived b cells.
Nat. Cell Biol. 21, 263–274.
Pagliuca, F.W., Millman, J.R., G€urtler, M., Segel, M., Van Dervort, A., Ryu, J.H.,
Peterson, Q.P., Greiner, D., and Melton, D.A. (2014). Generation of functional
human pancreatic b cells in vitro. Cell 159, 428–439.
Peterson, Q.P., Veres, A., Chen, L., Slama, M.Q., Kenty, J.H.R., Hassoun, S.,
Brown, M.R., Dou, H., Duffy, C.D., Zhou, Q., et al. (2020). Amethod for the gen-
eration of human stem cell-derived alpha cells. Nat. Commun. 11, 2241.
Pociot, F. (2017). Type 1 diabetes genome-wide association studies: not to be
lost in translation. Clin. Transl. Immunology 6, e162.
Pugliese, A. (2013). The multiple origins of Type 1 diabetes. Diabet. Med. 30,
135–146.
Pugliese, A. (2017). Autoreactive T cells in type 1 diabetes. J. Clin. Invest. 127,
2881–2891.
Regnell, S.E., Peterson, P., Trinh, L., Broberg, P., Leander, P., Lernmark, Å.,
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Peakman, M., Stangé, G., Martinson, L., Kroon, E., Brandon, E.P., Pipeleers,
D., and Roep, B.O. (2017). Immunogenicity of human embryonic stem cell-
derived beta cells. Diabetologia 60, 126–133.
Velthuis, J.H., Unger, W.W., Abreu, J.R., Duinkerken, G., Franken, K., Peak-
man, M., Bakker, A.H., Reker-Hadrup, S., Keymeulen, B., Drijfhout, J.W.,
et al. (2010). Simultaneous detection of circulating autoreactive CD8+ T-cells
specific for different islet cell-associated epitopes using combinatorial MHC
multimers. Diabetes 59, 1721–1730.
Veres, A., Faust, A.L., Bushnell, H.L., Engquist, E.N., Kenty, J.H., Harb, G.,
Poh, Y.C., Sintov, E., G€urtler, M., Pagliuca, F.W., et al. (2019). Charting cellular
identity during human in vitro b-cell differentiation. Nature 569, 368–373.
Virostko, J., Williams, J., Hilmes, M., Bowman, C., Wright, J.J., Du, L., Kang,
H., Russell, W.E., Powers, A.C., and Moore, D.J. (2019). Pancreas Volume De-
clines During the First Year After Diagnosis of Type 1 Diabetes and Exhibits
Altered Diffusion at Disease Onset. Diabetes Care 42, 248–257.
World Health Organization (2016). Global Report on Diabetes. https://www.
who.int/diabetes/global-report/en/.
10 Cell Reports 32, 107894, July 14, 2020
Report
ll
OPEN ACCESS
STAR+METHODS
KEY RESOURCES TABLE
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Antibodies
Rat anti-C-peptide Developmental Studies Hybridoma Bank (DHSB) GN-ID4, RRID:AB_2255626
Mouse anti-NKX6.1 DHSB F55A12, RRID:AB_532379
Mouse anti-glucagon Santa Cruz Biotech Cat#SC-514592, RRID:AB_2629431
Donkey anti-rat 594 Life Technologies Cat#A21209, RRID:AB_2535795
Donkey anti-mouse Alexa 647 Life Technologies Cat#A31571, RRID:AB_162542
Donkey anti-rabbit Alexa 488 Life Technologies Cat#A21206, RRID:AB_2535792
Donkey anti-rabbit Alexa 594 Life Technologies Cat#A21209, RRID:AB_2535795
Donkey anti-rabbit Alexa 647 Life Technologies Cat#A31573, RRID:AB_2536183
Donkey anti-goat Alexa 647 Life Technologies Cat#A21447, RRID:AB_141844
Donkey anti-sheep Alexa 488 Life Technologies Cat#A11015, RRID:AB_141362
Donkey anti-rat 488 Jackson Laboratories Cat#712-546-153, RRID:AB_2340686
Donkey anti-rat 405 Abcam Cat#ab175670, RRID:AB_11009056
Mouse Anti-HLA-ABC PE-conjugated Biolegend W6/32, Cat#311406, RRID:AB_314875
Mouse anti-HLA-E PE-conjugated Biolegend 3D12, Cat#342603, RRID:AB_1659250
Mouse anti-HLA-DR APC-conjugated Biolegend L243, Cat#307610, RRID:AB_314688
Mouse anti-PD-L1 APC-conjugated Biolegend 29E.2A3, Cat#329708, RRID:AB_940360
Mouse anti-CD3 PB-conjugated Biolegend UCHT1, Cat#300417, RRID:AB_493094
Mouse anti-CD8 PE-conjugated Biolegend T8-Leu2, Cat#344705, RRID:AB_1953243
Mouse anti-CD4 PE/Cy7-conjugated Biolegend RPA-T4, Cat#300511, RRID:AB_314079
Mouse anti-CD69 Alexa 647-conjugated Biolegend FN50, Cat#310918, RRID:AB_528871
Mouse anti-CD25 Alexa 700-conjugated Biolegend M-A251, Cat#356118, RRID:AB_2562168
Mouse anti-CD95/Fas APC-conjugated eBioscience DX2, Cat#17-0959-42, RRID:AB_10807091
Mouse anti-CD49a PE-conjugated BD Biosciences Cat#559596, RRID:AB_397288
Mouse anti-CD26 APC-conjugated Miltenyi Biotech Cat# 130-120-769, RRID:AB_2752189
Mouse anti-Oct4 Alexa 488-conjugated BD PharMingen Cat#560253, RRID:AB_1645304
Mouse anti-Sox2 PE-conjugated BD PharMingen Cat#560291, RRID:AB_1645334
Mouse anti-SSEA4 V450-conjugated BD PharMingen Cat#561156, RRID:AB_10896140
Mouse anti-TRA-1-60 (A647-conjugated BD PharMingen Cat#560850, RRID:AB_10565983
Rabbit anti-PERK Cell Signaling Tech. D11A8, Cat#5683S, RRID:AB_10841299
Rabbit anti-PDI Cell Signaling Tech. C81H6, Cat#3501S, RRID:AB_2156433
Rabbit anti-BIP Cell Signaling Tech. C50B12, Cat#3177S, RRID:AB_2119845
Rabbit anti-GAPDH Abcam Cat#ab181602, RRID:AB_2630358
Bacterial and Virus Strains
lentiCRISPRv2 Broad institute RRID: Addgene_52961
pHDM-vsvG, -tat, rev, gag/pol Harvard Medical School DNA Resource Core N/A
Sendai virus (SeV) Cytotune 2 kit Life Technologies Cat#A16517
Biological Samples
Human peripheral blood University of Massachusetts Medical School N/A
Human Peripheral Blood Leukapheresis Pack Stem Cell Technologies Cat#70500.1
Lenti-X 293T Cell Line Takara Bio Cat#632180
Chemicals, Peptides, and Recombinant Proteins
Activin A R&D Systems Cat#338-AC
Rock Inhibitor Y-27632 DNSK Cat#DNSK-Kl15-02
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RESOURCE AVAILABILITY
Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Douglas
A. Melton (dmelton@harvard.edu).
Materials Availability
This study did not generate any unique reagents. When appropriate, details and source information to synthesize non-commercially
available intermediate chemicals are provided and original literature source cited. The corresponding author can be contacted for
further details.
Data and Code Availability
The published report includes all data generated or analyzed during this study. No code was used or generated during this study.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
All procedures were performed in accordance with the IRB guidelines at Harvard University and University of Massachusetts Medical
School under IRB and ESCRO Protocols E00024. All iPSC lines were generated at the iPSC Core at Harvard Department of Stem
Cells and Regenerative Biology.
METHOD DETAILS
iPSC and PBMCs Derivation from Human Donors
For iPSC derivation from blood, Sendai virus (SeV) Cytotune 2 kit (Life Technologies, Cat#A16517) was used to infect erythroblast-
enriched populations following expansion. Briefly, 1 3 105 erythroblast-enriched populations were resuspended in 1mL of fresh
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Chir99021 Stemgent Cat#04-0004-10
KGF Peprotech Cat#100-19
Retinoic acid Sigma-Aldrich Cat# R2625
LDN193189 Sigma-Aldrich Cat#SML0559
Sant1 Sigma-Aldrich Cat#S4572
PBDU EMD Millipore Cat#524390
XXI EMD Millipore Cat#565790
Alk5i II Axxora Cat#ALX-270-445
T3 EMD Millipore Cat#642511
Betacellulin ThermoFisher Scientific Cat# 565790
Human IFN gamma R&D Systems Cat#285IF
Thapsigargin Sigma-Aldrich Cat#T9033
Critical Commercial Assays
MSD U-PLEX Metabolic group 1 kit MesoScale Discovery Cat# K151ACM
STEMdiff Cardiomyocyte Differentiation Kit Stem Cell Technologies Cat# #05010
Experimental Models: Cell Lines
Human iPSC-line T1D1 HSCI iPSC 3107-001
Human iPSC-line T1D2 HSCI iPSC 3107-002
Human iPSC-line T1D3 HSCI iPSC 3107-003
Human iPSC-line ND HSCI iPSC 3107-013
Software and Algorithms
QuantStudio 6 Flex Real-Time PCR system Applied Biosystems N/A
FlowJo v10 BD (Becton, Dickinson and Company) N/A
GraphPad Prism8 GraphPad Software N/A
nCounter NanoString technologies N/A
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StemSpan SFEM II with Erythroid expansion supplement. After that, Sendai virus vectors were reconstituted atMOI of 5 for KOS,MOI
of 5 for Myc andMOI of 3 for Klf4. Subsequently, virus suspension was added to the cells. On the following day cells were collected in
a 15 mL falcon tube and washed with StemSpan SFEM II with Erythroid expansion supplement by centrifugation at 300 3 g for
10 min. Two days post infection, cells were transferred from a well of a 12-well plate to a 6-well plate culture dish containing a mouse
embryonic fibroblast (MEF) feeder layer and cultured further for 2 days in hES Media (mTeSRTM1 - Stem Cell Technologies; 85850);
subsequently, media were changed daily. At 15 to 21 days post transduction, the transduced cells began to form colonies with iPSC
morphology, and visible colonies were handpicked and transferred onto 12-well plates.
Cell Culture
Human induced pluripotent stem-cell maintenance and differentiation were carried out as previously described (Pagliuca et al.,
2014). Induced pluripotent stem-cell lines were obtained from stocks maintained by the Melton laboratory. Induced pluripotent
stem cell lines weremaintained in cluster suspension culture format usingmTeSR3D (StemCell Technologies, 03950) in 500mL spin-
ner flasks (Corning, VWR) spinning at 70 rpm in an incubator at 37C, 5%CO2 and 100% humidity. Cells were passaged every 72h or
96h: induced human pluripotent stem-cell clusters were dissociated to single cells using gentle cell dissociation reagent (Stem Cell
Technologies; 07174) and light mechanical disruption, counted and seeded at 0.7 M cells/ml in mTeSR3D + 10 mM Y27632 (DNSK
International, DNSK-KI-15-02). Cell lines were authenticated by DNA fingerprinting, karyotyping (Cell Line Genetics) and all lines
tested negative on routine mycoplasma contamination verifications. Differentiation flasks were started 72 h after passaging by re-
placing mTeSR3D medium with the appropriate differentiation medium including growth factors and small molecule supplements
as previously described (Veres et al., 2019):
b Cell Differentiation Protocol
Stage 1: 24 hours in S1 medium supplemented with Activin A (100ng/ml), CHIR99021 (1.4 mg/ml) and Rock Inhibitor (10 mM), fol-
lowed by 48 hours Activin A (100ng/ml) only.
Stage 2: 72 hours in S2 medium supplemented with KGF (50ng/ml) and Rock Inhibitor (10 mM).
Stage 3: 48 hours in S3 medium supplemented with KGF (50ng/ml), LDN193189 (200nM), Sant1 (0.25 mM), retinoic acid (2 mM),
PBDU (500nM) and Rock Inhibitor (10 mM).
Stage 4: 5 days in S3 medium supplemented with KGF (50ng/ml), Sant1 (0.25 mM), retinoic acid (0.1 mM) and Rock Inhibitor
(10 mM).
Stage 5: 7 days in BE5 medium supplemented with Betacellulin (20ng/ml), XXI (1 mM), Alk5i-II (10 mM) and T3 (1 mM). Sant1
(0.25 mM) was added in days 1 to 3, and retinoic acid was added at 0.1 mM in days 1 to 3, then at 0.025 mM.
Stage 6: 14-21 days in S3 medium, changed every 48h.
a Cell Differentiation Protocol
Stages 1-2: Same as b Cell Differentiation Protocol
Stage 3: 48 hours in S3 medium supplemented with LDN193189 (200nM), retinoic acid (2 mM) and Rock Inhibitor (10 mM).
Stage 4: 5 days in S3 medium supplemented with LDN193189 (200nM) and Rock Inhibitor (10 mM).
Stage 5: 7 days in S3 medium supplemented with Alk5i-II (10 mM).
Stage 6: 28 days in S3 medium supplemented with PBDU (500nM).
During feeds, the differentiating clusters were allowed to gravity-settle for 5–10 min, medium was aspirated and 300 mL of pre-
warmed medium was added. All experiments involving human cells were approved by the Harvard University IRB and ESCRO
committees.
For cardiomyocyte differentiations, cells were seeded as clumps on 48 well plates and differentiated using the STEMdiff Cardio-
myocyte Differentiation Kit (Stem Cell Technologies, 05010).
Magnetic enrichment using CD49a and CD26
Stage 6 clusters were dissociated using TrypLE Express for 20 min at 37C. Cells were then quenched with DMEM + 10% FBS and
spun down. Remaining undissociated cell clusters weremechanically dissociated using a P1000 pipette. The dissociated single cells
were resuspended in sorting buffer (PBS + 1% BSA + 2 mM EDTA) and filtered through a 37-mmmesh filter. Cells were counted and
resuspended at a density of 10 million cells per 300 mL in 15 mL conical tubes. Cells were stained at room temperature for 20 min
using a 1:100 dilution of anti-human CD49a PE-conjugated (BD 559596) antibody, covered from light and agitated every 3 min.
Stained cells were washed twice with 15 mL of sorting buffer by spinning down (5 min, 300 g) and resuspended to their initial density
of 10 million cells per 300 ml. To label with microbeads, 40 mL of anti-PE UltraPure MACS microbreads (Miltenyi 130-105-639) were
added for each 10 million cells, and the cell solution was incubated for 15 min at 4C, agitated every 5 min. The stained cells were
washed twice as above, and resuspended to a target density of 25–30million cells per 500 ml. Volumes of 500 mL (containing nomore
than 30 million cells) were then magnetically separated on LS columns (Miltenyi 130-042-401) in a QuadroMACS separator (Miltenyi
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130-090-976) using the recommended protocol. Successful PE enrichment was verified by live-cell flow cytometry on an Attune NxT
(Invitrogen) flow cytometer. The negative cell fractionwas stained at room temperature for 20min using a 1:100 dilution of anti-human
CD26 APC-conjugated (Miltenyi Biotech 130-120-769) antibody, stained cells were washed as above and incubated with anti-APC
MACS microbreads (130-090-855). The cells were then magnetically separated on LS columns as described above.
Human Primary Immune Cell Isolation and Co-Culture Experiments
Weobtained blood from Type 1 Diabetic (T1D) and non-diabetic (ND), de-identified donors fromUniversity ofMassachusettsMedical
School. For unmatched blood, fresh Leukopaks from human donors were purchased (Stem Cell Technologies, 70500.1). Human pri-
mary peripheral mononuclear cells (PBMCs) were isolated using the density gradient medium, Ficoll-Paque Plus (GE health care life
sciences, 17144002) and the SepMate tubes (Stem Cell Technologies, 85450); T cells were isolated using EasySep Human T Cell
Isolation Kit (Stem Cell Technologies, 17951). Isolated T cells were cultured in X-VIVO 10 (Lonza, 04-380Q) media supplemented
with 5% Human AB Serum (Valley Biomedical, HP1022HI), 5% Fetal Bovine Serum (ThermoFisher Scientific, A3840101), 1% Peni-
cillin/Streptomycin (ThermoFisher Scientific, 15070063), GlutaMAX (ThermoFisher Scientific, 35050061), MEM Non-Essential Amino
Acids (ThermoFisher Scientific, 11140050).
T Cell Activation Assay
iPSC-b and a were used as target cells. Fifty to 100,000 target cells were plated on 96-well round bottom plates and treated with
IFNg, 100 ng/ml (Peprotech, 300-02) for 48h or thapsigargin, 5uM (Sigma Aldrich, T9033) for 5h before the assay. Cells were washed
to remove residual thapsigargin and IFNg. The immune/target cell ratio for co-culture is indicated in the figure legend. After a 48 hour
co-culture, CD4+ and CD8+ T cells were stained for T cell activation markers CD69 and CD25. T cells activated with Dynabeads Hu-
man T-Activator CD3/CD28 beads (ThermoFisher Scientific, 111.61) for 48 hours were used as positive control. The results are pre-
sented as adjusted mean MFI, with the mean MFI of unstimulated PBMCs subtracted from the mean MFI of activation.
Flow cytometry
Intracellular Marker Staining
Differentiated clusters, sampled from suspension cultures (1–2 ml), were dissociated using TrypLE Express (GIBCO, 12604013) at
37C, mechanically disrupted into single cells, fixed using 4% PFA for 30 min at room temperature and stored in PBS at 4C. For
staining, fixed single cells were incubated in Perm/Wash Buffer (BD Biosciences, 554723) for 30 min at room temperature, then incu-
bated in Perm/Wash Buffer with primary antibodies (1 h at room temperature), washed three times with Perm/Wash Buffer, incubated
with secondary antibodies in Perm/Wash Buffer (1 h at room temperature), washed three times and resuspended in Perm/Wash
Buffer. Stained cells were analyzed using the Attune NxT (ThermoFisher) flow cytometer. A sample gating strategy is shown in Fig-
ure S1. Results presented in this study are representative of more than ten differentiations.
Surface Marker Staining
PBS containing 4%Fetal Bovine Serum (FBS)was used as blocking and staining buffer. Immune cells or other dissociated single cells
were washed and blocked with blocking buffer for 30 min at 4C, then incubated in blocking buffer with conjugated antibodies (1h at
4C), washed three times with blocking buffer, fixed using 4%PFA for 30 min at room temperature and stored in PBS at 4C. Stained
cells were analyzed using the Attune NxT (ThermoFisher) flow cytometer.
Immunofluorescence Microscopy
Differentiated clusters were fixed in 4% PFA for 1 h at room temperature, washed, frozen in OCT (Tissue-Tek) and sectioned. For
staining, slides were incubated in CAS block (ThermoFisher, 008120) with primary antibody overnight at 4C, washed three times,
incubated in secondary antibody for 2 h at room temperature, washed, mounted in ProLong Diamond Antifade Mountant with
DAPI, covered with coverslips and sealed with clear nail polish. Representative regions were imaged using Zeiss.Z2 with Apotome
or Zeiss Cell Discoverer 7 microscopes. Images shown are representative of similar results in at least three biologically separate dif-
ferentiations from matched or similar stages.
Quantitative Real-time PCR (qPCR)
Cells were treated with TRIzol (ThermoFisher Scientific) for RNA extraction following the manufacturer’s protocol. Purified RNA was
reverse-transcribed into cDNA using the SuperScript IV first-strand synthesis kit (Invitrogen). GAD, PTPRN, G6PC2, SLC30A, IAPP
and INS probes for TaqMan assays were purchased from ThermoFisher Scientific. All qPCR assays were performed using a
QuantStudio 6 Flex Real-Time PCR system (Applied Biosystems).
NanoString gene array
Stage 6 cells from the b Cell Differentiation Protocol were enriched as described in the section ‘Magnetic enrichment using CD49a
and CD26.’ Prior to the nanostring assay, the enriched populations, CD49a+ (iPSC-b) and CD26+ (iPSC-a) fractions were lysed using
the RLT buffer (RNeasy Lysis Buffer, QIAGEN). An nCounter gene expression assay was performed according to the manufacturer’s
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protocol. The assay utilized a custom-made NanoString codeset designed to measure 24 transcripts, including 3 putative house-
keeping transcripts (see Table S2). The data was normalized to the average counts for all housekeeping genes in each sample
and analyzed with nSolver software (NanoString Technologies).
Protein Extraction and Immunoblotting
Cells were homogenized in RIPA buffer (ThermoFiscer, 89901) supplemented with protease and phosphatase inhibitors (Abcam,
201119). Total protein content was determined by BCA assay (ThermoFisher, 23225). Equal protein amounts (10 mg) were resolved
by SDS-PAGE and transferred to nitrocellulose membranes (EMDMillipore). Membranes were immunoblotted with the indicated an-
tibodies: PERK (Cell Signaling Technology, 5683S), PDI (Cell Signaling Technology, 3501S), BIP (Cell Signaling Technology, 3177S),
GAPDH (Abcam, 181602).
Cytokines Analysis
Supernatant of co-culture experiments were assayed using the MSD proinflammatory custom panel, a highly sensitive multiplex
enzyme-linked immunosorbent assay (ELISA) for quantitatively measuring cytokines including interferon g (IFN-g), interleukin (IL)-
1b, IL-2, IL17, and C-X-C motif chemokine 10 (CXCL10) from the supernatants using an electrochemiluminescent detection method
(MesoScale Discovery, Gaithersburg, MD, USA).
Viability and Apoptosis Assay
48h prior to co-culture with PBMCs, differentiated clusters were dissociated and reaggregated in V-bottom 96-well plates. PBMCs
were then co-cultured to re-aggregated iPSC-islets, with andwithout 5h pre-treatment with 5uM thapsigargin (SigmaAldrich, T9033).
For live counts of iPSC-b or iPSC-a, clusters were dissociated, and single cells were fixed (1% paraformaldehyde) and stained with
rat anti-C-peptide (DHSB, GN-ID4) andmouse anti-glucagon (Santa Cruz Biotech, SC-514592) antibodies for flow cytometry. For the
apoptosis assay, clusters were dissociated, and single cells were stained at room temperature for 30 min using a 1:100 dilution of
recently reported stem cell derived b-cell marker, anti-human CD49a (Veres et al., 2019) PE-conjugated (BD Biosciences,
559596), a-cell marker anti-human CD26 APC-conjugated (Miltenyi Biotech, 130-120-769), and Apopxin green indicator (Abcam,
ab176750).
Lentivirus Preparation and Transduction
Lentiviral particles were produced by transfecting 293T cells (Takara Bio, Mountain View, CA, USA) with the packaging vectors
pHDM-vsvg, pHDM-tat, pHDM-rev, and pHDM-gag/pol along with lentiviral backbone vectors using the TransIT-293 transfection
reagent (Mirus, Madison, WI, USA). The following lentiviral vectors were used: non-targeting guide RNA (50-TTTACGATC
TAGCGGCGTAG-30) or a B2M guide RNA (50-GCTACTCTCTCTTTCTGGCC-30) cloned into lentiCRISPRv2 [a gift from Feng Zhang
(Addgene plasmid # 52961 ; http://addgene:52961; RRID:Addgene_52961 (Sanjana et al., 2014)]. Lentiviral particles were concen-
trated 48 h and 72 h post transfection using the PEG-IT virus precipitation reagent (Fisher Scientific, Waltham, MA, USA) overnight at
4C followed by centrifugation at 1500 g for 30 min at 4C and stored at80C. For transduction, cell clusters collected from spinner
flask suspension cultures were dissociated in TrypLE Express (Life Technologies, Carlsbad, CA, USA) for 7min, followed bymechan-
ical dissociation and centrifugation at 300 g for 5 min at room temperature (RT). Cell pellets were resuspended at a density of 2.5
million cells/mL in the stage-matched medium with polybrene reagent (Santa Cruz, Dallas, TX, USA) at 8mg/mL. Single-cell suspen-
sions were combined with concentrated lentiviral particles and plated on ultra-low attachment six-well plates on a rocker plate set at
70rpm in a humid 37C incubator and 5% CO2.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses are described in detail where reported. Statistical analyses were carried out usingGraphpad Prism software. Sta-
tistical assays were performed as described in each figure legend. n represents number of biological replicates in all cases where
reported. Biological replicates refer to unique donor-derived batches of human islets or unique differentiations of iPSC-derived cells
produced from unique suspension cultures.
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